MD Anderson Cancer Center
1515 Holcombe Boulevard
Houston
Texas
77030
United States
Tel: 1-877-731-7527
Website: http://www.mdanderson.org/
309 articles about MD Anderson Cancer Center
-
Researchers find protein promotes cancer, suppresses anti-tumor immunity
12/2/2019
Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes also can fuel cancer development and suppress immune response to the disease.
-
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
12/2/2019
Cellectis announced that the first patient enrolled in the dose escalation Phase 1 clinical study for its UCART22 product candidate has been dosed at The University of Texas MD Anderson Cancer Center.
-
Soliton and Emphysys Enter Into a 3-year Development Agreement
11/21/2019
Soliton, Inc. announced that it has entered into a Cooperative Development Agreement with Emphysys, an interdisciplinary technology and product development firm just outside Boston, for design and engineering services related to the Company's acoustical shockwave technology.
-
Prostate cancer bone metastases thwart immunotherapy by producing TGF-β
11/14/2019
MD Anderson researchers find abundant cytokine crowds out helper T cells crucial to treatment
-
NANOBIOTIX Announces New Results From Pre-Clinical Immuno-Oncology Study at SITC 2019
11/12/2019
Data presented by MD Anderson demonstrates superiority for NBTXR3 activated by radiation therapy and anti-PD-1 in combination versus the radiation therapy and anti-PD-1 combination in an in vivo anti-PD-1-resistant model
-
Artios Pharma, MD Anderson and ShangPharma announce in-licensing agreement for DNA damage response inhibitor
11/6/2019
Artios Pharma Limited, The University of Texas MD Anderson Cancer Center and ShangPharma Innovation announce the in-licensing by Artios of a small-molecule ATR inhibitor programme, developed jointly by MD Anderson and ShangPharma.
-
Under the new deal, Artios Pharma licensed rights to research, develop, manufacture and commercialize products globally from a small-molecule ATR inhibitor program that was jointly developed by MD Anderson and ShangPharma.
-
Takeda and MD Anderson Announce Collaboration to Accelerate the Development of Clinical-Stage, Off-The-Shelf CAR NK-Cell Therapy Platform
11/5/2019
Ongoing Phase 1/2a Study of CD19 CAR-NK with Pivotal Study Expected to Enroll Patients in 2021
-
They announced an exclusive license deal and research agreement to develop cord-blood derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies.
-
Soliton's Recent Positive Data Increases Potential Fibrotic Indications
10/29/2019
Success in Treatment of Fibrotic Scar Could Lead to Other Indications
-
Ziopharm said the collaboration with the vaunted cancer research center will use non-viral gene transfer to stably express and clinically evaluate neoantigen-specific T-cell receptors in T cells.
-
Ziopharm Oncology and MD Anderson Cancer Center Announce New R&D Agreement to Expand TCR-T Program
10/28/2019
Accelerates capability for TCR library expansion of T-cell receptors (TCRs) targeting neoatigens, including in hotspots
-
Cue Biopharma to Present at the Oppenheimer Houston Oncology Summit at the University of Texas MD Anderson Cancer Center
10/15/2019
Cue Biopharma, Inc. announced that it will present at the Houston Oncology Summit at the University of Texas MD Anderson Cancer Center on Thursday, October 17, 2019 at 10:40 a.m. CT in Houston, Texas.
-
Oppenheimer To Host Houston Oncology Summit At The University of Texas MD Anderson Cancer Center
10/10/2019
Oppenheimer & Co. Inc. will host its Houston Oncology Summit on October 17, 2019 at the University of Texas MD Anderson Cancer Center.
-
It was another busy week for clinical trials. Here’s a look.
-
Soliton Announces Tattoo Technology Article Published in Medical Journal and Selected as Editor's Choice
10/3/2019
Article Reviewing Rapid Acoustic Pulse Technology to be included in next "Lasers in Surgery and Medicine" Journal
-
According to multiple reports, President Donald Trump is set to pick Hahn, a noted radiation oncologist, as the successor to Scott Gottlieb.
-
Soliton Completes Keloid POC Clinical Trial Treatments
10/1/2019
Soliton, Inc. announced it has completed all patient treatments in the keloid scar proof-of-concept trial.
-
PARP inhibitor plus chemotherapy improves progression-free survival for advanced ovarian cancer patients
9/28/2019
Phase III trial validates the benefit of veliparib for patients without a BRCA mutation
-
New clinical data shows that Eli Lilly’s investigational oncology drug pegilodecakin, in combination with a checkpoint inhibitor, could be a potential new treatment for patients with non-small cell lung cancer and kidney cancer.